-$0.07 Earnings Per Share Expected for ENDRA Life Sciences Inc. (NASDAQ:NDRA) This Quarter

Brokerages expect ENDRA Life Sciences Inc. (NASDAQ:NDRAGet Rating) to announce ($0.07) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ENDRA Life Sciences’ earnings. ENDRA Life Sciences posted earnings per share of ($0.08) in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.5%. The company is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that ENDRA Life Sciences will report full-year earnings of ($0.26) per share for the current year. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover ENDRA Life Sciences.

ENDRA Life Sciences (NASDAQ:NDRAGet Rating) last announced its earnings results on Wednesday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter. During the same period in the prior year, the business posted ($0.10) EPS.

NDRA has been the subject of a number of research reports. Zacks Investment Research upgraded shares of ENDRA Life Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. HC Wainwright cut their price objective on shares of ENDRA Life Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, April 7th.

Large investors have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new position in shares of ENDRA Life Sciences in the third quarter valued at approximately $26,000. Royal Bank of Canada raised its position in shares of ENDRA Life Sciences by 65.3% in the second quarter. Royal Bank of Canada now owns 25,310 shares of the company’s stock valued at $55,000 after buying an additional 10,000 shares during the last quarter. Raymond James & Associates acquired a new position in ENDRA Life Sciences during the fourth quarter worth approximately $49,000. Virtu Financial LLC acquired a new position in ENDRA Life Sciences during the fourth quarter worth approximately $50,000. Finally, Renaissance Technologies LLC acquired a new position in ENDRA Life Sciences during the fourth quarter worth approximately $150,000. 10.03% of the stock is owned by institutional investors and hedge funds.

NDRA traded down $0.01 during midday trading on Friday, reaching $0.19. 29,062 shares of the company’s stock were exchanged, compared to its average volume of 2,222,361. The business’s 50-day moving average price is $0.32 and its 200 day moving average price is $0.62. ENDRA Life Sciences has a 1-year low of $0.18 and a 1-year high of $2.44.

About ENDRA Life Sciences (Get Rating)

ENDRA Life Sciences Inc develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

Featured Articles

Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.